Recent expansions of novel strategies towards the drug targeting into the brain

References

• Parent AC. M.B. Carpenter’s Human Neuroanatomy. Michigan: Williams & Wilkins; 1995.
   Google Scholar
• Cosgrove KP, Mazure CM, Staley JK. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry. 2007;62(8):847–855. doi:10.1016/j.biopsych.2007.03.00117544382
   PubMed Web of Science ®Google Scholar
• Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109–133. doi:10.1007/s40263-016-0405-928101766
   PubMed Web of Science ®Google Scholar
• Nagpal K, Singh SK, Mishra DN. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin Drug Deliv. 2013;10(7):927–955. doi:10.1517/17425247.2013.76235423330786
   PubMed Web of Science ®Google Scholar
• Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9(1):2241–2257. doi:10.2147/IJN.S6128824872687
   PubMedGoogle Scholar
• Odiba A, Ottah V, Ottah C, et al. Therapeutic nanomedicine surmounts the limitations of pharmacotherapy. Open Med. 2017;12:271–287. doi:10.1515/med-2017-0041
   Web of Science ®Google Scholar
• Agrahari V, Agrahari V, Mitra AK. Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities. Ther Deliv. 2016;7(4):257–278.27010987
   PubMed Web of Science ®Google Scholar
• Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discovery. 2016;15(4):275–292.26794270
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B. 2016;6(4):268–286.27471668
   PubMed Web of Science ®Google Scholar
• Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor?. Ageing Res Rev. 2014;14:19–30. doi:10.1016/j.arr.2014.01.00424503004
   PubMed Web of Science ®Google Scholar
• Neuwelt E, Abbott NJ, Abrey L, et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7(1):84–96. doi:10.1016/S1474-4422(07)70326-518093565
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90–105, 151. doi:10.1124/mi.3.2.9014993430
   PubMedGoogle Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev. 2012;64(7):640–665. doi:10.1016/j.addr.2011.11.01022154620
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011;8(1):7. doi:10.1186/2045-8118-8-721349155
   PubMedGoogle Scholar
• de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol. 2007;47:323–355. doi:10.1146/annurev.pharmtox.47.120505.10523716961459
   PubMed Web of Science ®Google Scholar
• Terasaki T, Tsuji A. Drug delivery to the brain utilizing blood-brain barrier transport systems. J Controlled Release. 1994;29(1):163–169. doi:10.1016/0168-3659(94)90132-5
   Web of Science ®Google Scholar
• Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol. 1998;165(3):201–211.9767674
   PubMed Web of Science ®Google Scholar
• Garg T, Bhandari S, Rath G, Goyal AK. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target. 2015;23(10):865–887. doi:10.3109/1061186X.2015.102993025835469
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24(9):1759–1771. doi:10.1007/s11095-007-9379-017619996
   PubMed Web of Science ®Google Scholar
• Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy. 2009;1(6):983–993. doi:10.2217/imt.09.7520635914
   PubMed Web of Science ®Google Scholar
• Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613–631. doi:10.1146/annurev-pharmtox-010814-12485225340933
   PubMed Web of Science ®Google Scholar
• Mena I, Cotzias GC. Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med. 1975;292(4):181–184. doi:10.1056/NEJM1975012329204041109209
   PubMed Web of Science ®Google Scholar
• Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004;18(9):998–1000. doi:10.1096/fj.04-1517fje15084516
   PubMedGoogle Scholar
• Priller J, Flugel A, Wehner T, et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. 2001;7(12):1356–1361. doi:10.1038/nm1201-135611726978
   PubMedGoogle Scholar
• Tong HI, Kang W, Davy PM, et al. Monocyte Trafficking, Engraftment, and Delivery of Nanoparticles and an Exogenous Gene into the Acutely Inflamed Brain Tissue - Evaluations on Monocyte-Based Delivery System for the Central Nervous System. PLoS One. 2016;11(4):e0154022. doi:10.1371/journal.pone.015402227115998
   PubMed Web of Science ®Google Scholar
• Arora W. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine. 2012;7:3445–3471. doi:10.2147/IJN.S3032022848170
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv. 2011;8(4):415–433. doi:10.1517/17425247.2011.55945721348773
   PubMed Web of Science ®Google Scholar
• Bay DC, Turner RJ. Small Multidrug Resistance Efflux Pumps In: Li X-Z, Elkins CA, Zgurskaya HI, editors. Efflux-Mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications. Cham: Springer International Publishing; 2016:45–71.
   Google Scholar
• Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci. 2003;92(9):1739–1753. doi:10.1002/jps.1042412949994
   PubMed Web of Science ®Google Scholar
• Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015;1628(Pt B):298–316. doi:10.1016/j.brainres.2015.07.00526187753
   PubMedGoogle Scholar
• Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86–98. doi:10.1602/neurorx.2.1.8615717060
   PubMedGoogle Scholar
• Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60(2):196–209. doi:10.1124/pr.107.0710918560012
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2(3):106–113.8796867
   PubMedGoogle Scholar
• Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–3478. doi:10.1073/pnas.05058539710716719
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38(6):339–348.12529928
   PubMed Web of Science ®Google Scholar
• Alexander A, Saraf S, Saraf S, et al. Amalgamation of stem cells with nanotechnology: A unique therapeutic approach. Curr Stem Cell Res Ther. 2018;14(2):83–92.
   Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opin Drug Deliv. 2018;15(6):589–617. doi:10.1080/17425247.2018.147105829733231
   PubMed Web of Science ®Google Scholar
• Khare S, Ajazuddin AA, Amit. N. Biomedical applications of nanobiotechnology for drug design, delivery and diagnostics. Res J Pharm Technol. 2014;7(8):915–925.
   Google Scholar
• Jane B. Reece, Martha R. Taylor, Eric J. Simon, Jean L. Dickey.Campbell Biology—Concepts and Connections. North Carolina: Pearson Education; 2009.
   Google Scholar
• Alexander A, Saraf S, Saraf S. A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates. Drug Dev Ind Pharm. 2015;41(12):1954–1961. doi:10.3109/03639045.2015.101116725678314
   PubMed Web of Science ®Google Scholar
• Agrawal M, Tripathi DK, Saraf S, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s disease. J Controlled Release. 2017;260:61–77. doi:10.1016/j.jconrel.2017.05.019
   PubMed Web of Science ®Google Scholar
• Pedro Ramos-Cabrer FC. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomedicine. 2012;8(1):951–960.
   Google Scholar
• Salade L, Wauthoz N, Deleu M, et al. Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia. Int J Nanomedicine. 2017;13:8531–8543.
   Google Scholar
• Szebeni J, Baranyi L, Savay S, et al. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res. 2002;12(1–2):165–172. doi:10.1081/LPR-12000479012604051
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi:10.1186/1556-276X-8-10223432972
   PubMed Web of Science ®Google Scholar
• Débora B, Vieira LFG. Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier. Int J Nanomedicine. 2016;11:5381–5414. doi:10.2147/IJN.S11721027799765
   PubMedGoogle Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs. 2005;16(7):691–707.16027517
   PubMed Web of Science ®Google Scholar
• Barbara Kneidl MP, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9(1):4387–4398. doi:10.2147/IJN.S4929725258529
   PubMedGoogle Scholar
• Callum Ross MT, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2018;13:8507–8522. doi:10.2147/IJN.S18311730587974
   PubMedGoogle Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–999. doi:10.2147/IJN.S6886125678787
   PubMed Web of Science ®Google Scholar
• Ross C, Taylor M, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2018;13:8507–8522. doi:10.2147/IJN.S18311730587974
   PubMed Web of Science ®Google Scholar
• Zheng X, Shao X, Zhang C, et al. Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer’s disease. Pharm Res. 2015;32(12):3837–3849. doi:10.1007/s11095-015-1744-926113236
   PubMed Web of Science ®Google Scholar
• Al Asmari AK, Ullah Z, Tariq M, Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther. 2016;10:205–215. doi:10.2147/DDDT.S93937
   PubMedGoogle Scholar
• Xiao W, Fu Q, Zhao Y, et al. Ascorbic acid-modified brain-specific liposomes drug delivery system with “lock-in” function. Chem Phys Lipids. 2019. doi:10.1016/j.chemphyslip.2019.01.005
   Web of Science ®Google Scholar
• Li X, Xiao H, Lin C, et al. Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis. Int J Nanomedicine. 2019;14:649–665. doi:10.2147/IJN.S18981930697048
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen CL, Rajesh R. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. Acta Biomater. 2019;87:207–222. doi:10.1016/j.actbio.2019.01.06530716553
   PubMed Web of Science ®Google Scholar
• Batista CA, Larson RG, Kotov NA. Nonadditivity of nanoparticle interactions. Science (New York, NY). 2015;350(6257):1242477. doi:10.1126/science.1242477
   Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (London, England). 2016;11(6):673–692. doi:10.2217/nnm.16.5
   PubMed Web of Science ®Google Scholar
• Schmalz G, Hickel R, van Landuyt KL, Reichl FX. Nanoparticles in dentistry. Dental Mater. 2017;33(11):1298–1314. doi:10.1016/j.dental.2017.08.193
   PubMed Web of Science ®Google Scholar
• Dwivedi GR, Singh DP, Sharma A, Darokar MP, Srivastava SK. Nano particles: emerging warheads against bacterial superbugs. Curr Top Med Chem. 2016;16(18):1963–1975.26876525
   PubMed Web of Science ®Google Scholar
• Abrahamse H, Kruger CA, Kadanyo S, Mishra A. Nanoparticles for advanced photodynamic therapy of cancer. Photomed Laser Surg. 2017;35(11):581–588.28937916
   PubMed Web of Science ®Google Scholar
• Portioli C, Bovi M, Benati D, et al. Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications. J Biomed Mater Res Part A. 2017;105(3):847–858.
   PubMed Web of Science ®Google Scholar
• Alexander A, Ajazuddin KJ, Saraf S, Saraf S. Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications. J Controlled Release. 2013;172(3):715–729.
   PubMed Web of Science ®Google Scholar
• Alexander A, Ajazuddin KJ, Saraf S, Saraf S. Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate. J Pharm Pharmacol. 2014;66(9):1240–1250.24824413
   PubMed Web of Science ®Google Scholar
• Alexander A, Ajazuddin PRJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Controlled Release. 2016;241:110–124.
   PubMed Web of Science ®Google Scholar
• Maria João Gomes J, Bruno S. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomedicine. 2014;9(1):1757–1769.24741312
   PubMedGoogle Scholar
• Song H, Wei M, Zhang N, et al. Enhanced permeability of blood–brain barrier and targeting function of brain via borneol-modified chemically solid lipid nanoparticle. Int J Nanomedicine. 2018;13:1869–1879.29636606
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Controlled Release. 2004;100(1):5–28.
   PubMed Web of Science ®Google Scholar
• Alexander A, Ajazuddin M, Swarna M, Sharma M, Tripathi D. Polymers and permeation enhancers: specialized components of mucoadhesives. Stamford J Pharm Sci. 2011;4(1):91–95.
   Google Scholar
• Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm. 2010;74(2):157–163.19755158
   PubMed Web of Science ®Google Scholar
• Alexander A, Dwivedi S, Giri TK, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Controlled Release. 2012;164(1):26–40.
   PubMed Web of Science ®Google Scholar
• Bruno Fonseca-Santos MPDG, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2015;10(1):4981–5003.26345528
   PubMedGoogle Scholar
• Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Controlled Release. 2017;268:364–389.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Archunan G, Sivakumar M, et al. Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomedicine. 2018;13:5561–5576.30271147
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chang YH, Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)poly(epsiloncaprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid. Mater Sci Eng C Mater Biol Appl. 2019;96:114–128.30606517
   PubMed Web of Science ®Google Scholar
• Li H, Tong Y, Bai L, et al. Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma. Int J Biol Macromol. 2018;107(Pt A):204–211.28863897
   PubMedGoogle Scholar
• Fernandes J, Ghate MV, Basu Mallik S, Lewis SA. Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor. Int J Pharm. 2018;547(1–2):563–571.29906562
   PubMedGoogle Scholar
• Rukmangathen R, Yallamalli IM, Yalavarthi PR. Biopharmaceutical potential of selegiline loaded chitosan nanoparticles in the management of Parkinson’s disease. Curr Drug Discov Technol. Epub April 18, 2018. doi:10.2174/1570163815666180418144019
   PubMedGoogle Scholar
• Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res. 2010;27(9):1759–1771.20593303
   PubMed Web of Science ®Google Scholar
• Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L. The blood-brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem Biophys Res Commun. 2010;394(4):871–876.20206605
   PubMed Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, Volceanov A. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10(4):269.
   PubMed Web of Science ®Google Scholar
• Ren J, Shen S, Wang D, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33(11):3324–3333.22281423
   PubMed Web of Science ®Google Scholar
• Qiao R, Jia Q, Huwel S, et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano. 2012;6(4):3304–3310.22443607
   PubMed Web of Science ®Google Scholar
• Frigell J, Garcia I, Gomez-Vallejo V, Llop J, Penades S. 68Ga-labeled gold glyconanoparticles for exploring blood-brain barrier permeability: preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation. J Am Chem Soc. 2014;136(1):449–457.24320878
   PubMed Web of Science ®Google Scholar
• Tomitaka A, Ota S, Nishimoto K, Arami H, Takemura Y, Nair M. Dynamic magnetic characterization and magnetic particle imaging enhancement of magnetic-gold core-shell nanoparticles. Nanoscale. 2019;11:6489–6496.
   PubMedGoogle Scholar
• Zhao L, Li Y, Zhu J, et al. Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy. J Nanobiotechnology. 2019;17(1):30.30782154
   PubMedGoogle Scholar
• Fahmy HM, Fathy MM, Abd-Elbadia RA, Elshemey WM. Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: in vivo study. Life Sci. 2019;222:94–102.30826496
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Y, Yang Y, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine. 2010;6(3):427–441.20056170
   PubMed Web of Science ®Google Scholar
• Li X, Tsibouklis J, Weng T, et al. Nano carriers for drug transport across the blood-brain barrier. J Drug Target. 2017;25(1):17–28.27126681
   PubMed Web of Science ®Google Scholar
• Alexander A, Ajazuddin KJ, Saraf S, Saraf S. Polyethylene glycol (PEG)-Poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications. Eur J Pharm Biopharm. 2014;88(3):575–585.25092423
   PubMed Web of Science ®Google Scholar
• Li XCY. Study on synthesis and chloramphenicol release of poly (2-hydroxyethylmethacrylate-co-acrylamide) hydrogels. Chin J Chem Eng. 2008;16:640–645.
   Web of Science ®Google Scholar
• Weng T, Guo J, Li X, et al. Synthesis, chloramphenicol uptake, and in vitro release of poly(AMPS–TEA-Co-AAm) gels with affinity for both water and alcohols. Int J Polym Mater Polym Biomater. 2014;63(2):73–79.
   Web of Science ®Google Scholar
• Chen W, Zou Y, Zhong Z, Haag R. Cyclo(RGD)-decorated reduction-responsive nanogels mediate targeted chemotherapy of integrin overexpressing human glioblastoma in vivo. Small. 2017;13(6):1–9.
   Web of Science ®Google Scholar
• Warren G, Makarov E, Lu Y, et al. Amphiphilic cationic nanogels as brain-targeted carriers for activated nucleoside reverse transcriptase inhibitors. J J Neuroimmune Pharmacol. 2015;10(1):88–101.
   PubMed Web of Science ®Google Scholar
• Azadi A, Hamidi M, Khoshayand MR, Amini M, Rouini MR. Preparation and optimization of surface-treated methotrexate-loaded nanogels intended for brain delivery. Carbohydr Polym. 2012;90(1):462–471.24751066
   PubMed Web of Science ®Google Scholar
• Seok GELL. Invention of polysaccharide-based nanoparticles for enhancing drug permeability across the blood brain barrier. NSTI-Nanotech. 2008;2:379–381.
   Google Scholar
• Li X, Cui Y. Study on synthesis and chloramphenicol release of poly(2-hydroxyethylmethacrylate-co-acrylamide) Hydrogels. Chin J Chem Eng. 2008;16(4):640–645.
   Web of Science ®Google Scholar
• Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928–939.19278222
   PubMed Web of Science ®Google Scholar
• Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010;27(7):260–273.20929336
   PubMed Web of Science ®Google Scholar
• Shobo A, Pamreddy A, Kruger HG, et al. Enhanced brain penetration of pretomanid by intranasal administration of an oil-in-water nanoemulsion. Nanomedicine (London, England). 2018;13(9):997–1008. doi:10.2217/nnm-2017-0365
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Naqvi AA, et al. Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol. 2018;46(4):717–729. doi:10.1080/21691401.2017.133702428604104
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Abbas Naqvi A, et al. The effect of safranal loaded mucoadhesive nanoemulsion on oxidative stress markers in cerebral ischemia. Artif Cells Nanomed Biotechnol. 2017;45(4):775–787. doi:10.1080/21691401.2016.122865927609117
   PubMed Web of Science ®Google Scholar
• Abdou EM, Kandil SM, Miniawy H. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int J Pharm. 2017;529(1–2):667–677. doi:10.1016/j.ijpharm.2017.07.03028729175
   PubMed Web of Science ®Google Scholar
• Dordevic SM, Cekic ND, Savic MM, et al. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: design, characterization and in vivo pharmacokinetic evaluation. Int J Pharm. 2015;493(1–2):40–54. doi:10.1016/j.ijpharm.2015.07.00726209070
   PubMedGoogle Scholar
• Tan SL, Stanslas J, Basri M, et al. Nanoemulsion-based parenteral drug delivery system of carbamazepine: preparation, characterization, stability evaluation and blood-brain pharmacokinetics. Curr Drug Deliv. 2015;12(6):795–804.26324229
   PubMed Web of Science ®Google Scholar
• Bonferoni MC, Rossi S. Nanoemulsions for “Nose-to-Brain” Drug Delivery. Pharmaceutics 2019;11(2):84–101.
   Google Scholar
• Yan H, Wang J, Yi P, et al. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem Commun (Cambridge, England). 2011;47(28):8130–8132. doi:10.1039/c1cc12007g
   PubMed Web of Science ®Google Scholar
• He H, Li Y, Jia XR, et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials. 2011;32(2):478–487. doi:10.1016/j.biomaterials.2010.09.00220934215
   PubMed Web of Science ®Google Scholar
• Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm. 2008;5(1):105–116. doi:10.1021/mp700086j18171013
   PubMedGoogle Scholar
• Verma C, Janghel A, Deo S, et al. Comprehensive advancement on nanomedicinesalong with its various biomedical applications. Res J Pharm Technol. 2015;8(7):945. doi:10.5958/0974-360X.2015.00159.6
   Google Scholar
• Lu Y, Han S, Zheng H, et al. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system. Int J Nanomedicine. 2018;13:5937–5952. doi:10.2147/IJN.S17541830323584
   PubMed Web of Science ®Google Scholar
• Lu Y, Han S, Zheng H, et al. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system. Int J Nanomedicine. 2018;13:5937–5952. doi:10.2147/IJN.S17541830323584
   PubMed Web of Science ®Google Scholar
• Gothwal A, Nakhate KT, Alexander A, Ajazuddin GU. Boosted memory and improved brain bioavailability of rivastigmine: targeting effort to the brain using covalently tethered lower generation PAMAM dendrimers with lactoferrin. Mol Pharm. 2018;15(10):4538–4549. doi:10.1021/acs.molpharmaceut.8b0053730156844
   PubMedGoogle Scholar
• Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15):3899–3908. doi:10.1016/j.biomaterials.2012.02.00422364698
   PubMed Web of Science ®Google Scholar
• Ghaderi S, Ramesh B, Seifalian AM. Fluorescence nanoparticles “quantum dots” as drug delivery system and their toxicity: a review. J Drug Target. 2011;19(7):475–486. doi:10.3109/1061186X.2010.52622720964619
   PubMed Web of Science ®Google Scholar
• Shafq Al-Azzawi DM, Guildford AL, Phillips G, Santin M. Dendrimeric poly(Epsilon-Lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer’s disease. Int J Mol Sci. 2018;19(10):3224. doi:10.3390/ijms19103224
   PubMed Web of Science ®Google Scholar
• Gao J, Chen K, Xie R, et al. In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots. Bioconjug Chem. 2010;21(4):604–609. doi:10.1021/bc900323v20369817
   PubMed Web of Science ®Google Scholar
• Gao X, Chen J, Chen J, Wu B, Chen H, Jiang X. Quantum dots bearing lectin-functionalized nanoparticles as a platform for in vivo brain imaging. Bioconjug Chem. 2008;19(11):2189–2195. doi:10.1021/bc800269818922029
   PubMedGoogle Scholar
• Qiao L, Sun T, Zheng X, Zheng M, Xie Z. Exploring the optimal ratio of d-glucose/l-aspartic acid for targeting carbon dots toward brain tumor cells. Mater Sci Eng C Mater Biol Appl. 2018;85:1–6. doi:10.1016/j.msec.2017.12.01129407137
   PubMedGoogle Scholar
• Tang J, Huang N, Zhang X, et al. Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomedicine. 2017;12:3899–3911. doi:10.2147/IJN.S13316628579776
   PubMed Web of Science ®Google Scholar
• Yang HY, Fu Y, Jang MS, et al. CdSe@ZnS/ZnS quantum dots loaded in polymeric micelles as a pH-triggerable targeting fluorescence imaging probe for detecting cerebral ischemic area. Colloids Surf B Biointerfaces. 2017;155:497–506. doi:10.1016/j.colsurfb.2017.04.05428475986
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Controlled Release. 2018;281:139–177. doi:10.1016/j.jconrel.2018.05.011
   PubMed Web of Science ®Google Scholar
• Alam S, Khan ZI, Mustafa G, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine. 2012;7:5705–5718. doi:10.2147/IJN.S3532923180965
   PubMed Web of Science ®Google Scholar
• Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44–52. doi:10.1016/j.lfs.2017.12.02529277310
   PubMed Web of Science ®Google Scholar
• Alexander A, Saraf S. Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer’s disease. Neural Regener Res. 2018;13(12):2102. doi:10.4103/1673-5374.233432
   PubMed Web of Science ®Google Scholar
• Nigam K, Kaur A, Tyagi A, et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv Transl Res. 2019. doi:10.1007/s13346-019-00622-5
   PubMed Web of Science ®Google Scholar
• Musumeci T, Serapide MF, Pellitteri R, et al. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. Eur J Pharm Biopharm. 2018;133:309–320. doi:10.1016/j.ejpb.2018.11.00230399400
   PubMed Web of Science ®Google Scholar
• Chu L, Wang A, Ni L, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 2018;25(1):1634–1641.30176744
   PubMed Web of Science ®Google Scholar
• Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2012;64(7):686–700. doi:10.1016/j.addr.2011.10.00722100125
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chou PR. Neuroprotection against degeneration of sk-N-mc cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin. J Pharm Sci. 2014;103(8):2484–2497. doi:10.1002/jps.2408125041794
   PubMed Web of Science ®Google Scholar
• Su Z, Xing L, Chen Y, et al. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharm. 2014;11(6):1823–1834. doi:10.1021/mp500238m24779677
   PubMedGoogle Scholar
• Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Controlled Release. 2016;227:23–37. doi:10.1016/j.jconrel.2016.02.026
   PubMed Web of Science ®Google Scholar
• Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543–557. doi:10.1038/nmat244219525947
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428–437. doi:10.1016/j.addr.2009.03.00919376175
   PubMed Web of Science ®Google Scholar
• Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137–143. doi:10.1038/nnano.2012.23723334168
   PubMed Web of Science ®Google Scholar
• Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31(10):1111–1137. doi:10.1016/S1357-2725(99)00070-910582342
   PubMed Web of Science ®Google Scholar
• Xie R, Dong L, Du Y, et al. In vivo metabolic labeling of sialoglycans in the mouse brain by using a liposome-assisted bioorthogonal reporter strategy. Proc Natl Acad Sci U S A. 2016;113(19):5173–5178. doi:10.1073/pnas.151652411327125855
   PubMedGoogle Scholar